CEREVANCE
Cerevance is a developer of novel therapeutics intended to advance new medicines for serious neurological diseases.The company's therapeutics applies it's technology called NETSseq to reveal transcriptional and epigenetic differences between specific cell types in mature human brains, enabling healthcare providers to detect and tackle the early onset of various neurological diseases.
CEREVANCE
Industry:
Biotechnology Life Science Therapeutics
Founded:
2016-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.cerevance.com
Total Employee:
101+
Status:
Active
Total Funding:
91.5 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network
Similar Organizations
Rainier Therapeutics
Rainier Therapeutics is a developer of cancer therapeutics technology intended to offer advanced targeted therapy for bladder cancer.
InVivo Biosystems
InVivo Biosystems is using alternative, non-mammalian model organisms in early biological and biomedical research.
Neurogene
Neurogene is a developer of genetic medicines intended to improve patient outcomes for neurological disorders.
NeuroNascent
Neuronascent discovers and develops small molecule therapeutics for depression and neurodegenerative diseases.
NeoPhore
NeoPhore is a provider of novel small molecule therapies intended to treat cancer through stimulation of the immune system.
Neuron23
Neuron23 is a developer of drugs intended to treat Parkinson's disease and Alzheimer's disease.
ND BioSciences
ND BioSciences is developing diagnostics and therapies for neurodegenerative diseases.
Neuroglee Therapeutics
Neuroglee Therapeutics is a digital therapeutic platform created to treat patients in the early stages of the disease.
Vigil Neuroscience
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
Vedanta Biosciences
Vedanta Biosciences creates microbiome-derived therapies to address immune and infectious diseases by modulating the gut microbiota.
Verve Therapeutics
Verve Therapeutics is a genetic medicine firm that is developing treatments for cardiovascular disease.
Metabolic Solutions Development
Metabolic Solutions Development develops innovative therapeutics based on a novel pharmacological method to treat type two diabetes.
Mogrify
Mogrify® will transform the development of ex vivo cell therapies and pioneer a new class of in vivo reprogramming therapies.
Mitobridge
Mitobridge is discovering and developing small molecule therapeutics that improve mitochondrial functions.
Leyden Labs
Leyden Labs provides a platform that targets commonalities of viral families to protect humanity from known and future viruses.
Life Biosciences
Life Biosciences is a developer of drugs designed to promote longevity and find treatments for age-related diseases.
Lassen Therapeutics
Lassen Therapeutics is developing novel, best-in-class biotherapeutics to improve the lives of patients suffering from serious diseases.
Arbor Biotechnologies
Arbor Biotechnologies is an operator of a bio-discovery company intended to provide human diagnostic development services.
Axcella
Axcella is a biotechnology company that treats diseases using endogenous metabolic modulators.
A2 Biotherapeutics
A2 Biotherapeutics develops novel medicines for serious illness.
EnteroBiotix
EnteroBiotix is a developer of novel medicinal products intended to restore health and prevent bacterial infections.
EnGeneIC
EnGeneIC develops and commercializes the treatment of cancer through the targeted delivery of therapeutic agents directly to cancer cells.
Epirus Biopharmaceuticals
Epirus Biopharmaceuticals develops biosimilar monoclonal antibodies and therapeutic proteins for emerging markets.
Edesa Biotech
Edesa develops treatments for dermatological and anorectal diseases. Edesa merged with Stellar Biotechnologies in 2019.
Erasca
Erasca is a developer of oncology drugs intended to provide precision oncology options.
ELEX Biotech LLC
Elex biotech is engaged in developing drugs for the treatment of cardiovascular diseases.
Broad Institute
The Broad Institute brings together a diverse group of individuals from across its partner institutions to confront biomedical challenges.
Biopalette
Biopalette is a operator of a platform intended to offer gene-editing techniques.
BioSkryb
BioSkryb is a developer of genomic amplification technologies that deliver unprecedented coverage for various gene sequencing applications.
Federation Bio
Federation Bio is a microbial therapeutics company targeting diseases in which the human microbiome can play a curative role.
Trailhead Biosystems
Trailhead Biosystems is a biotechnology company that develops human cells for drug discovery and cell therapies.
Transine Therapeutics
Transine Therapeutics is a developer of biotech platform enhancing therapeutics for the treatment of human disease.
TNAX Biopharma
TNAX Biopharma is a developer of pharmaceuticals drugs intended to improve the quality of life of patients.
Think Bioscience
Think Bioscience is reimagining synthetic biology by guiding the design and assembly of better medicines through the use of living systems.
Tenaya Therapeutics
Tenaya Therapeutics is a developer of novel therapies designed to offer treatment for heart disease.
Kyverna Therapeutics
Kyverna Therapeutics is pioneering a new class of therapies and cures for serious autoimmune diseases.
Kern Systems
Kern Systems leverages the power of enzymes and software to create the world's most scalable DNA data storage infrastructure.
Kalbe Genexine Biologics
Kalbe Genexine Biologics is developing innovative biologic therapy for high unmet medical needs in largely underserved areas.
Wugen
Wugen is developing off-the-shelf cellular therapies targeting solid tumors and hematologic malignancies
Sana Biotechnology
Sana Biotechnology is a developer of engineered cells intended to be used as medicine for patients.
Strand Therapeutics
Strand Therapeutics is a biopharmaceutical company applying synthetic biology to RNA therapeutics to develop single dose mRNA treatments.
Senda Biosciences
Senda Biosciences is a therapeutics platform company leveraging unprecedented insights into the molecular connections between humans.
SolAeroMed
SolAeroMed is a developer of a novel therapeutic used to treat obstructive lung diseases.
Savran Technologies
Savran Technologies offers non-invasive diagnostics based on capture and analysis of rare cells.
Spero Therapeutics
Spero Therapeutics develops therapeutics for treatment of gram-negative infections.
Seranova Bio
Seranova Bio develops companion diagnostics or therapeutics to treat autoimmune disease or other autoantibody-driven diseases.
SQZ Biotech
SQZ Biotech features a cell engineering technology designed to deliver a diverse set of materials into patient cells.
Scioto Biosciences
Scioto is a developer of Activated Bacterial Therapeutics platform.
SeromYx Systems
SeromYx Systems provides insight into the immune function to discover and develop vaccines, immunotherapies, drugs, and diagnostics.
HepaRegeniX
HepaRegeniX is developing drugs for treating acute and chronic liver diseases.
ImmPACT Bio
ImmPACT Bio USA is developing novel cell therapies for treating cancer.
Imophoron
Imophoron is the developer of a novel next-generation rapid-response vaccine platform, ADDomer(TM).
GALY
GALY develops biomaterials through biotechnology and synthetic biology in order to discover new ways to produce natural things.
Gamma Biosciences
Gamma Biosciences is a next-generation bioprocessing for advanced therapies by acquiring or investing in high-potential businesses.
Garuda Therapeutics
Garuda Therapeutics is developing off-the-shelf hematopoietic stem cell (HSC) therapies to treat severe and life-threatening diseases.
ONI
ONI is a pioneer of super-resolution microscopy, making this advanced technology accessible to new generations of researchers.
Cadent Therapeutics
Cadent Therapeutics develops novel medicines that tune and modulate brain rhythms for patients with serious neurological disease.
CND Life Sciences
CND Life Sciences develops an accurate, evidence-based tool that helps confirm a diagnosis of synucleinopathy.
Cyrus Biotechnology
Cyrus Biotechnology is a developer of Rosetta software platform that solves drug discovery problems.
Cardiol Therapeutics
Cardiol Therapeutics develops innovative cannabidiol medicines for heart disease.
Creyon Bio
Reinventing drug development from the ground up to make safe, effective oligonucleotide-based medicines possible on demand.
Padlock Therapeutics
Padlock is developing medicines targeting PADs, immune complexes in autoimmune diseases, and more.
Phoenicis
Phoenicis focuses on developing therapies to provide hope and relief to people living with rare disease.
Prelude Therapeutics
Prelude Therapeutics designs and develops small molecule therapies targeting key drivers of cancer cell growth and resistance.
Pipeline Therapeutics
Pipeline Therapeutics is a developer of regenerative therapies designed to promote functional recovery of neurological diseases.
Psygen Labs
Psygen is a manufacturer of pharmaceutical-grade psychedelic drug products for clinical research and therapeutic applications.
Current Employees Featured
Brad Margus Co-founder & CEO @ Cerevance
Co-founder & CEO
2016-10-01
Ben Robbins Board Observer @ Cerevance
Board Observer
2020-03-01
Mark Carlton CSO @ Cerevance
CSO
2016-12-01
Roland Burli VP of Drug Discovery @ Cerevance
VP of Drug Discovery
Lee Dawson Vice President of Neuroscience @ Cerevance
Vice President of Neuroscience
David Margolin SVP of Clinical & Translational Medicine @ Cerevance
SVP of Clinical & Translational Medicine
Robert Middlebrook CFO @ Cerevance
CFO
Nathaniel Heintz Chief Scientific Advisor @ Cerevance
Chief Scientific Advisor
Craig Thompson Chief Executive Officer @ Cerevance
Chief Executive Officer
2022-04-01
Founder
Investors List
Lightstone Ventures
Lightstone Ventures investment in Series B - Cerevance
Foresite Capital
Foresite Capital investment in Series B - Cerevance
Casdin Capital
Casdin Capital investment in Series B - Cerevance
Dolby Family Ventures
Dolby Family Ventures investment in Series B - Cerevance
GV
GV investment in Series B - Cerevance
Dementia Discovery Fund
Dementia Discovery Fund investment in Series B - Cerevance
Takeda Ventures
Takeda Ventures investment in Series B - Cerevance
UPMC Enterprises
UPMC Enterprises investment in Series B - Cerevance
Bill Gates
Bill Gates investment in Series B - Cerevance
Takeda
Takeda investment in Venture Round - Cerevance
Official Site Inspections
http://www.cerevance.com Semrush global rank: 4.4 M Semrush visits lastest month: 2.54 K
- Host name: aacb0a264e514dd48.awsglobalaccelerator.com
- IP address: 99.83.190.102
- Location: Seattle United States
- Latitude: 47.54
- Longitude: -122.3032
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98108
More informations about "Cerevance"
Cerevance - Crunchbase Company Profile & Funding
Organization. Cerevance . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ... Cerevance is a …See details»
Cerevance
Jan 25, 2017 Cerevance has published the full results from the Phase 2 clinical trial of solengepras, in eClinicalMedicine, a peer-reviewed journal published by The Lancet Discovery …See details»
About - Cerevance
Cerevance is focused on the development of cell-type specific treatments for neurodegenerative, psychiatric, and CNS-controlled metabolic disorders. Leveraging a vast and expanding …See details»
Cerevance: Revenue, Worth, Valuation & Competitors 2025
About Cerevance. Cerevance is a Pharmaceuticals related company founded in 2016 and based in Boston with 61 employees an estimated revenue of $6.1M, and. It has 10 competitors …See details»
Cerevance - Funding, Financials, Valuation & Investors - Crunchbase
Cerevance is funded by 17 investors. MQB Partners and Lightstone Ventures are the most recent investors. Cerevance has a post-money valuation in the range of $500M to $1B as of Apr 25, …See details»
Cerevance - LinkedIn
Today marks an exciting milestone for Cerevance with the release of positive data from our Phase 1 study of CVN293, a KCNK13 inhibitor, in healthy volunteers.See details»
Cerevance - Contacts, Employees, Board Members, Advisors
Organization. Cerevance . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies ... Cerevance has 10 current employee profiles, including …See details»
Cerevance - Company Profile - Tracxn
Feb 23, 2025 Cerevance is focused on discovering and developing novel therapeutics for neurological and psychiatric disorders. The company has licensed technology created in the …See details»
Cerevance Company Profile - Office Locations, Competitors ... - Craft
Cerevance is a new pharmaceutical company focused on central nervous system diseases. The Company's strengths include a powerful technology platform, a pipeline of novel discovery …See details»
Cerevance - Portfolio Company Profile, Executives and Private …
Cerevance is a private drug discovery and development company focused on brain diseases. See Cerevance's complete profile, including its private equity owner and the number of its …See details»
Cerevance 2025 Company Profile: Valuation, Funding & Investors
Cerevance General Information Description. Developer of novel therapeutics intended for new medicines formulation for central nervous system diseases. The company's therapeutics …See details»
Cerevance - Work in biotech
Cerevance uses their Nuclear Enriched Transcript Sort sequencing (NETSseq) platform and machine learning to discover the next generation of central nervous system disease …See details»
Craig Thompson - CEO, Cerevance - Advancing Novel, Precision
Craig Thompson is the Chief Executive Officer of Cerevance ( https://www.cerevance.com/about ), a private, clinical-stage drug discovery and development comp...See details»
Cerevance - SPEEDA Edge
Cerevance is a clinical-stage biopharmaceutical company dedicated to advancing precision treatments for central nervous system (CNS) disorders. The company's core technology is its …See details»
Accueil - Cerevance
Feb 21, 2025 Ce site est dédié aux cytopénies auto-immunes de l’enfant et de l’adolescent, un ensemble de maladies auto-immunes du sang s’attaquant aux plaquettes (PTI/Purpura …See details»
Cerevance
Welcome to the CNS revolution. Cerevance is a revolutionary pharmaceutical company using the proprietary NETSseq platform to develop novel symptomatic and disease modifying therapies …See details»
Cerevance
Cerevance is a private pharmaceutical company whose lead program, CVN424, a first-in-class compound acting on a novel target, recently demonstrated significant and meaningful efficacy …See details»
Cerevance
Boston, MA – July 21, 2020 – Cerevance, a private drug discovery and development company focused on brain diseases, has expanded its Series B financing round, adding $20 million to …See details»
Media - Cerevance
Cerevance to deliver a poster presentation at the upcoming Federation of European Neuroscience Societies (FENS) Forum 2024, taking place in Vienna, Austria, from June 25 – 29, 2024. …See details»
Cerevance
Cerevance has published the full results from the Phase 2 clinical trial of solengepras, in eClinicalMedicine, a peer-reviewed journal published by The Lancet Discovery Science Suite. …See details»